Last reviewed · How we verify
NCT04092673: Zotatifin
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
Phase 1, PHASE2 trial testing eFT226 in Solid Tumor, Adult in 30 participants. Currently enrolling.
31 December 2024
Quick facts
| Lead sponsor | Effector Therapeutics |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 25 October 2019 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 March 2025 |
| Sites | 14 locations across United States |
Drugs / interventions tested
- eFT226
- Sotorasib (SOTORASIB) — full drug profile →
- Fulvestrant (fulvestrant) — full drug profile →
- Abemaciclib (abemaciclib) — full drug profile →
- Trastuzumab (trastuzumab) — full drug profile →
Conditions studied
- Solid Tumor, Adult — all drugs for Solid Tumor, Adult →
Sponsor
Effector Therapeutics — full company profile →
Who can join
18 and older, any sex, with Solid Tumor, Adult. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of Zotatifin (eFT226) in subjects with selected advanced solid tumor malignancies.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting RNA structures with small molecules.
Childs-Disney JL, Yang X, Gibaut QMR, Tong Y, et al · · 2022 · cited 417× · PMID 35941229 · DOI 10.1038/s41573-022-00521-4 -
Alternative approaches to target Myc for cancer treatment.
Wang C, Zhang J, Yin J, Gan Y, et al · · 2021 · cited 160× · PMID 33692331 · DOI 10.1038/s41392-021-00500-y -
Protein synthesis control in cancer: selectivity and therapeutic targeting.
Kovalski JR, Kuzuoglu-Ozturk D, Ruggero D. · · 2022 · cited 98× · PMID 35315941 · DOI 10.15252/embj.2021109823 -
Repurposing anticancer drugs for the management of COVID-19.
El Bairi K, Trapani D, Petrillo A, Le Page C, et al · · 2020 · cited 59× · PMID 33125946 · DOI 10.1016/j.ejca.2020.09.014 -
The Role of Breast Cancer Stem Cells in Chemoresistance and Metastasis in Triple-Negative Breast Cancer.
He L, Wick N, Germans SK, Peng Y. · · 2021 · cited 55× · PMID 34944829 · DOI 10.3390/cancers13246209 -
General and Target-Specific DExD/H RNA Helicases in Eukaryotic Translation Initiation.
Shen L, Pelletier J. · · 2020 · cited 50× · PMID 32575790 · DOI 10.3390/ijms21124402 -
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer.
Casacuberta-Serra S, González-Larreategui Í, Capitán-Leo D, Soucek L. · · 2024 · cited 43× · PMID 39164274 · DOI 10.1038/s41392-024-01907-z -
Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML.
Nishida Y, Zhao R, Heese LE, Akiyama H, et al · · 2021 · cited 39× · PMID 34127794 · DOI 10.1038/s41375-021-01308-z
Verify or expand the search:
- PubMed search for NCT04092673
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Solid Tumor, Adult
Currently open trials in the same condition.
- NCT07139990 — Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM) · Phase 1 · recruiting
- NCT06398418 — R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients · Phase 1 · recruiting
- NCT06682793 — A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor · Phase 1, PHASE2 · recruiting
- NCT07137195 — Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Hebei) · NA · active not recruiting
- NCT06714617 — Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors · Phase 1 · active not recruiting
Other Effector Therapeutics trials
Trials by the same sponsor.
- NCT04632381 — Intravenous Zotatifin in Adults With Mild or Moderate COVID-19 · Phase 1 · completed
- NCT04622007 — Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART) · Phase 2 · active not recruiting
- NCT03690141 — An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer · Phase 2 · terminated
- NCT03616834 — Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy · Phase 2 · completed
- NCT03318562 — A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC · Phase 2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04092673 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Effector Therapeutics
- Last refreshed: 21 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04092673.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing